Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA

Introduction: Adding LAMA to LABA/ICS is recommended to improve control in patients with persistent asthma. Methods: This observational, retrospective, before-and-after study considered patients diagnosed with asthma who started LABA/ICS + LAMA treatment (triple therapy, TT) between 1 January 2017 a...

ver descrição completa

Detalhes bibliográficos
Autores: Plaza, V, Domínguez-Ortega, J, Alsina, DGS, Lo Re, D, Sicras-Mainar, A
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p17372
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17372
Access Level:acceso abierto
Palavra-chave:dual therapy
triple therapy
asthma
long-acting muscarinic antagonists
exacerbations
costs
id ES_1f8f3c2f93f6d7ba32f8e2890aaedef4
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p17372
network_acronym_str ES
network_name_str España
repository_id_str
spelling Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABAPlaza, VDomínguez-Ortega, JAlsina, DGSLo Re, DSicras-Mainar, Adual therapytriple therapyasthmalong-acting muscarinic antagonistsexacerbationscostsIntroduction: Adding LAMA to LABA/ICS is recommended to improve control in patients with persistent asthma. Methods: This observational, retrospective, before-and-after study considered patients diagnosed with asthma who started LABA/ICS + LAMA treatment (triple therapy, TT) between 1 January 2017 and 31 December 2018 and had been treated with LABA/ICS (dual therapy, DT) in the year before. Changes in lung function and exacerbation rates, healthcare resource utilization, and healthcare and non-healthcare costs (<euro>2019) were estimated in patients with asthma in clinical practices in Spain. Data from computerized medical records from seven Spanish regions were collected +/- 1 year of LAMA addition. Results: 4740 patients (64.1 years old [SD: 16.3]) were included. TT reduced the incidence of exacerbations by 16.7% (p < 0.044) and the number of patients with exacerbations by 8.5% (p < 0.001) compared to previous DT. The rate of patients with severe exacerbations requiring systemic corticosteroids and their hospitalization rates significantly decreased by 22.5% and 29.5%. TT significantly improved FEV1, FVC, and FEV1/FVC, saving <euro>571/patient for society. Younger patients with asthma (18-44 years old) and patients with severe asthma (FEV1 < 60%) performed better upon the initiation of TT. Conclusions: TT reduced asthma exacerbations, improved lung function and reduced healthcare costs vs. DT, particularly in patients requiring systemic corticosteroids to treat severe exacerbations.MDPI2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17372PharmaceuticalsISSN: 14248247reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p173722026-06-14T12:41:47Z
dc.title.none.fl_str_mv Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
title Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
spellingShingle Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
Plaza, V
dual therapy
triple therapy
asthma
long-acting muscarinic antagonists
exacerbations
costs
title_short Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
title_full Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
title_fullStr Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
title_full_unstemmed Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
title_sort Comprehensive Observational Study in a Large Cohort of Asthma Patients after Adding LAMA to ICS/LABA
dc.creator.none.fl_str_mv Plaza, V
Domínguez-Ortega, J
Alsina, DGS
Lo Re, D
Sicras-Mainar, A
author Plaza, V
author_facet Plaza, V
Domínguez-Ortega, J
Alsina, DGS
Lo Re, D
Sicras-Mainar, A
author_role author
author2 Domínguez-Ortega, J
Alsina, DGS
Lo Re, D
Sicras-Mainar, A
author2_role author
author
author
author
dc.subject.none.fl_str_mv dual therapy
triple therapy
asthma
long-acting muscarinic antagonists
exacerbations
costs
topic dual therapy
triple therapy
asthma
long-acting muscarinic antagonists
exacerbations
costs
description Introduction: Adding LAMA to LABA/ICS is recommended to improve control in patients with persistent asthma. Methods: This observational, retrospective, before-and-after study considered patients diagnosed with asthma who started LABA/ICS + LAMA treatment (triple therapy, TT) between 1 January 2017 and 31 December 2018 and had been treated with LABA/ICS (dual therapy, DT) in the year before. Changes in lung function and exacerbation rates, healthcare resource utilization, and healthcare and non-healthcare costs (<euro>2019) were estimated in patients with asthma in clinical practices in Spain. Data from computerized medical records from seven Spanish regions were collected +/- 1 year of LAMA addition. Results: 4740 patients (64.1 years old [SD: 16.3]) were included. TT reduced the incidence of exacerbations by 16.7% (p < 0.044) and the number of patients with exacerbations by 8.5% (p < 0.001) compared to previous DT. The rate of patients with severe exacerbations requiring systemic corticosteroids and their hospitalization rates significantly decreased by 22.5% and 29.5%. TT significantly improved FEV1, FVC, and FEV1/FVC, saving <euro>571/patient for society. Younger patients with asthma (18-44 years old) and patients with severe asthma (FEV1 < 60%) performed better upon the initiation of TT. Conclusions: TT reduced asthma exacerbations, improved lung function and reduced healthcare costs vs. DT, particularly in patients requiring systemic corticosteroids to treat severe exacerbations.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17372
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17372
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv Pharmaceuticals
ISSN: 14248247
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404407523704832
score 15,812455

Registos relacionados